Neuroimaging and genetics of antidepressant response to sleep deprivation: Implications for drug development

Current Pharmaceutical Design

Volumn 15, Issue 22, 2009, Pages 2637-2649

  Benedetti, Francesco ^a   Smeraldi, Enrico ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antidepressant; Dopamine; Glutamate; GSK 3; Norepinephrine; Serotonin; Sleep deprivation; Synaptic homeostasis

Indexed keywords

AMINEPTINE; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; DOPAMINE; GLUTAMATE RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID; NORADRENALIN; PINDOLOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE;

BIOLOGICAL RHYTHM; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN REGION; CLINICAL EFFECTIVENESS; DEPRESSION; DOPAMINE RELEASE; DRUG EFFICACY; DRUG TARGETING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HUMAN; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; PHOTOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DEPRIVATION; SPIN LABELING; STIMULUS RESPONSE; TREATMENT DURATION;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; CHRONOTHERAPY; DIAGNOSTIC IMAGING; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE IMAGING; MOOD DISORDERS; POSITRON-EMISSION TOMOGRAPHY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SLEEP DEPRIVATION; THYROID HORMONES;

EID: 69249088552     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788957447     Document Type: Review

References (182)

1. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: A critical overview. Pharmacol Rev 2006; 58: 115-34.
2. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135-370.
3. Benedetti F, Barbini B, Colombo C, Smeraldi E. Chronotherapeutics in a psychiatric ward. Sleep Med Rev 2007; 11: 509-22.
4. Wirz-Justice A, Terman M, Oren DA, Goodwin FK, Kripke DF, Whybrow PC, et al. Brightening depression. Science 2004; 303: 467-9.
5. Wu JC, Buchsbaum M, Bunney WE, Jr. Clinical neurochemical implications of sleep deprivation's effects on the anterior cingulate of depressed responders. Neuropsychopharmacology 2001; 25: S74-8.
6. Gillin JC, Buchsbaum M, Wu J, Clark C, Bunney W, Jr. Sleep deprivation as a model experimental antidepressant treatment: Findings from functional brain imaging. Depress Anxiety 2001; 14: 37-49.
7. Wirz-Justice A, Benedetti F, Berger M, Lam RW, Martiny K, Terman M, et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med 2005; 35: 939-44.
8. Wirz-Justice A, Van den Hoofdakker RH. Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 1999; 46: 445-53.
9. Wu JC, Bunney WE. The biological basis of an antidepressant response to sleep deprivation and relapse: Review and hypothesis. Am J Psychiatry 1990; 147: 14-21.
10. Bunney JN, Potkin SG. Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. Br Med Bull 2008; 86: 23-32.
11. Benedetti F, Colombo C, Barbini B, Campori E, Smeraldi E. Ongoing lithium treatment prevents relapse after total sleep deprivation. J Clin Psychopharmacol 1999; 19: 240-5.
12. Baving L, Maes H, Bohus M, Lis S, Krieger S, Olbrich H, et al. Can negative self-schemes in depressives be altered through sleep deprivation? J Affect Disord 1997; 42: 93-101.
13. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C. Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression - A placebo-controlled trial. Neuropsychopharmacology 1999; 20: 380-5.
14. Colombo C, Lucca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: Replication of main effects and interaction. Psychiatry Res 2000; 95: 43-53.
15. Benedetti F, Barbini B, Fulgosi MC, Colombo C, Dallaspezia S, Pontiggia A, et al. Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: Acute response and long-term remission rates. J Clin Psychiatry 2005; 66: 1535-40.
16. Leibenluft E, Moul DE, Schwartz PJ, Madden PA, Wehr TA. A clinical trial of sleep deprivation in combination with antidepressant medication. Psychiatry Res 1993; 46: 213-27.
17. Leibenluft E, Wehr TA. Is sleep deprivation useful in the treatment of depression? Am J Psychiatry 1992; 149: 159-68.
18. Selvi Y, Gulec M, Agargun MY, Besiroglu L. Mood changes after sleep deprivation in morningness-eveningness chronotypes in healthy individuals. J Sleep Res 2007; 16: 241-4.
19. Roy-Byrne PP, Uhde TW, Post RM. Effects of one night's sleep deprivation on mood and behavior in panic disorder. Patients with panic disorder compared with depressed patients and normal controls. Arch Gen Psychiatry 1986; 43: 895-9.
20. Joffe RT, Swinson RP. Total sleep deprivation in patients with obsessive-compulsive disorder. Acta Psychiatr Scand 1988; 77: 483-7.
21. Boivin DB, Czeisler CA, Dijk DJ, Duffy JF, Folkard S, Minors DS, et al. Complex interaction of the sleep-wake cycle and circadian phase modulates mood in healthy subjects. Arch Gen Psychiatry 1997; 54: 145-52.
22. Koorengevel KM, Beersma DG, den Boer JA, van den Hoofdakker RH. A forced desynchrony study of circadian pacemaker characteristics in seasonal affective disorder. J Biol Rhythms 2002; 17: 463-75.
23. Wirz-Justice A. Diurnal variation of depressive symptoms. Dialogues Clin Neurosci 2008; 10: 337-43.
24. Reinink E, Bouhuys N, Wirz-Justice A, van den Hoofdakker R. Prediction of the antidepressant response to total sleep deprivation by diurnal variation of mood. Psychiatry Res 1990; 32: 113-24.
25. Haug HJ. Prediction of sleep deprivation outcome by diurnal variation of mood. Biol Psychiatry 1992; 31: 271-8.
26. Maier W, Philipp M, Schlegel S, Heuser I, Wiedemann K, Benkert O. Diagnostic determinants of response to treatment with tricyclic antidepressants: A polydiagnostic approach. Psychiatry Res 1989; 30: 83-93.
27. Joyce PR, Porter RJ, Mulder RT, Luty SE, McKenzie JM, Miller AL, et al. Reversed diurnal variation in depression: Associations with a differential antidepressant response, tryptophan: Large neutral amino acid ratio and serotonin transporter polymorphisms. Psychol Med 2005; 35: 511-7.
28. Benedetti F, Dallaspezia S, Fulgosi MC, Barbini B, Colombo C, Smeraldi E. Phase advance is an actimetric correlate of antidepressant response to sleep deprivation and light therapy in bipolar depression. Chronobiol Int 2007; 24: 921-37.
29. Sprouse J. Pharmacological modulation of circadian rhythms: A new drug target in psychotherapeutics. Expert Opin Ther Targets 2004; 8: 25-38
30. Sprouse J, Braselton J, Reynolds L. Fluoxetine modulates the circadian biological clock via phase advances of suprachiasmatic nucleus neuronal firing. Biol Psychiatry 2006; 60: 896-9.
31. Cole MG, Muller HF. Sleep deprivation in the treatment of elderly depressed patients. J Am Geriatr Soc 1976; 24: 308-13.
32. Demet EM, Chicz-Demet A, Fallon JH, Sokolski KN. Sleep deprivation therapy in depressive illness and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 1999; 23: 753-84.
33. Fahndrich E. Sleep deprivation therapy of depressive syndromes in schizophrenic disorders (author's transl). Nervenarzt 1982; 53: 279-93.
34. Parry BL, Curran ML, Stuenkel CA, Yokimozo M, Tam L, Powell KA, et al. Can critically timed sleep deprivation be useful in pregnancy and postpartum depressions? J Affect Disord 2000; 60: 201-12.
35. Parry BL, Cover H, Mostofi N, LeVeau B, Sependa PA, Resnick A, et al. Early versus late partial sleep deprivation in patients with premenstrual dysphoric disorder and normal comparison subjects. Am J Psychiatry 1995; 152: 404-12.
36. Vogel GW, Thurmond A, Gibbons P, Sloan K, Walker M. REM sleep reduction effects on depression syndromes. Arch Gen Psychiatry 1975; 32: 765-77.
37. Barbini B, Colombo C, Benedetti F, Campori E, Bellodi L, Smeraldi E. The unipolar-bipolar dichotomy and the response to sleep deprivation. Psychiatry Res 1998; 79: 43-50.
38. Wehr TA, Sack DA, Norman E. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987; 144: 201-4.
39. Wehr TA. Improvement of depression and triggering of mania by sleep deprivation. JAMA 1992; 267: 548-51.
40. Barbini B, Bertelli S, Colombo C, Smeraldi E. Sleep loss, a possible factor in augmenting manic episode. Psychiatry Res 1996; 15: 121-5.
41. Barbini B, Benedetti F, Colombo C, Dotoli D, Bernasconi A, Cigala-Fulgosi M, et al. Dark therapy for mania: A pilot study. Bipolar Disord 2005; 7: 98-101.
42. Benedetti F, Fresi F, Maccioni P, Smeraldi E. Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav Brain Res 2008; 187: 221-7.
43. Machado-Vieira R, Kapczinski F, Soares JC. Perspectives for the development of animal models of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 209-24.
44. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60: 497-502.
45. Bauer M, Grof P, Rasgon N, Bschor T, Glenn T, Whybrow PC. Temporal relation between sleep and mood in patients with bipolar disorder. Bipolar Disord 2006; 8: 160-7.
46. Lenox RH, Frazer A. Mechanism of action of antidepressants and mood stabilizers. In: Davis KL, Charney D, Coyle JT, Nemeroff C, Eds. Neuropsychopharmacology: The fifth generation of progress. Philadelphia: Lippincott Williams & Wilkins 2002; pp. 1139-63.
47. Benedetti F, Barbini B, Lucca A, Campori E, Colombo C, Smeraldi E. Sleep deprivation hastens the antidepressant action of fluoxetine. European Archives of Psychiatry & Clinical Neuroscience 1997; 247: 100-3.
48. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51: 248-51.
49. Artigas F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378-83.
50. Adrien J. Neurobiological bases for the relation between sleep and depression. Sleep Med Rev 2002; 6: 341-51.
51. Gardner JP, Fornal CA, Jacobs BL. Effects of sleep deprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat. Neuropsychopharmacology 1997; 17: 72-81.
52. Lopez-Rodriguez F, Wilson CL, Maidment NT, Poland RE, Engel J. Total sleep deprivation increases extracellular serotonin in the rat hippocampus. Neuroscience 2003; 121: 523-30.
53. Hery F, Pujol JF, Lopez M, Macon J, Glowinski J. Increased synthesis and utilization of serotonin in the central nervous system of the rat during paradoxical sleep deprivation. Brain Res 1970; 21: 391-403.
54. Cramer H, Tagliamonte A, Tagliamonte P, Perez-Cruet J, Gessa GL. Stimulation of brain serotonin turnover by paradoxical sleep deprivation in intact and hypophysectomized rats. Brain Res 1973; 54: 372-5.
55. Asikainen M, Deboer T, Porkka-Heiskanen T, Stenberg D, Tobler I. Sleep deprivation increases brain serotonin turnover in the Djungarian hamster. Neurosci Lett 1995; 198: 21-4.
56. Maudhuit C, Jolas T, Chastanet M, Hamon M, Adrien J. Reduced inhibitory potency of serotonin reuptake blockers on central serotoninergic neurons in rats selectively deprived of rapid eye movement sleep. Biol Psychiatry 1996; 40: 1000-7.
57. Santos R, Carlini EA. Serotonin receptor activation in rats previously deprived of REM sleep. Pharmacol Biochem Behav 1983; 18: 501-7.
58. Salomon RM, Delgado PL, Licinio J, Krystal JH, Heninger GR, Charney DS. Effects of sleep deprivation on serotonin function in depression. Biol Psychiatry 1994; 36: 840-6.
59. Serretti A, Benedetti F, Zanardi R, Smeraldi E. The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry 2005.
60. Benedetti F, Barbini B, Bernasconi A, Fulgosi MC, Colombo C, Dallaspezia S, et al. Serotonin 5-HT(2A) receptor gene variants influence antidepressant response to repeated total sleep deprivation in bipolar depression. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1863-6.
61. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, et al. Allelic variation of human serotonin trasporter gene expression. J Neurochem 1996; 66: 2621-4.
62. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527-31.
63. Hanna GL, Himle JA, Curtis GC, Koram DQ, VanderWeele J, Leventhal BL, et al. Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 1998; 18: 102-11.
64. Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, McFinton PR, et al. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 1998; 155: 207-13.
65. Greenberg BD, Tolliver TJ, Huang SJ, Li Q, Bengel D, Murphy DL. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999; 88: 83-7.
66. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000; 47: 643-9.
67. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508-11.
68. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105-7.
69. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587-90.
70. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, et al. Initial conditions of serotonin transporter kinetics and genotype: Influence on SSRI treatment trial outcome. Biol Psychiatry 2002; 51: 723-32.
71. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L. 5-HTTLPR polymorphism of the serotonin transporter gene predicts nonremission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003; 23: 563-7.
72. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004; 174: 525-9.
73. Benedetti F, Serretti A, Colombo C, Campori E, Barbini B, Di Bella D, et al. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression. Am J Psychiatry 1999; 156: 1450-2
74. Benedetti F, Barbini B, Bernasconi A, Fulgosi MC, Campori E, Colombo C, et al. Lithium overcomes the influence of 5-HTTLPR gene polymorphism on antidepressant response to sleep deprivation. J Clin Psychopharmacol 2008; 28: 249-51.
75. Benedetti F, Colombo C, Serretti A, Lorenzi C, Pontiggia A, Barbini B, et al. Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Biol Psychiatry 2003; 54: 687-92.
76. Price LH, Charney DS, Delgado PL, Heninger GR. Lithium and serotonin function: Implications for the serotonin hypothesis of depression. Psychopharmacology 1990; 100: 3-12.
77. Carli M, Reader TA. Regulation of central serotonin transporters by chronic lithium: An autoradiographic study. Synapse 1997; 27: 83-9.
78. Carli M, Afkhami-Dastjerdian S, Reader TA. Effects of a chronic lithium treatment on cortical serotonin uptake sites and 5-HT1A receptors. Neurochem Res 1997; 22: 427-35.
79. Sanders-Bush E, Fentress H, Hazelwood L. Serotonin 5-ht2 receptors: molecular and genomic diversity. Mol Interven 2003; 3: 319-30.
80. Polesskaya OO, Sokolov BP. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002; 67: 812-22.
81. Turecki G, Briere R, Dewar K, Antonetti T, Lesage AD, Seguin M, et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999; 156: 1456-8
82. Jokela M, Keltikangas-Jarvinen L, Kivimaki M, Puttonen S, Elovainio M, Rontu R, et al. Serotonin receptor 2A gene and the influence of childhood maternal nurturance on adulthood depressive symptoms. Arch Gen Psychiatry 2007; 64: 356-60.
83. Popa D, Lena C, Fabre V, Prenat C, Gingrich J, Escourrou P, et al. Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. J Neurosci 2005; 25: 11231-8.
84. Kang RH, Choi MJ, Paik JW, Hahn SW, Lee MS. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Int J Psychiatry Med 2007; 37: 315-29.
85. Wirz-Justice A, Puhringer W, Hole G. Sleep deprivation and clomipramine in endogenous depression. Lancet 1976; 2: 912.
86. Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004; 29: 252-65.
87. Yamauchi M, Miyara T, Matsushima T, Imanishi T. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res 2006; 1067: 164-9.
88. Hariri AR, Drabant EM, Weinberger DR. Imaging genetics: Perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol Psychiatry 2006; 59: 888-97
89. Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: A genetic susceptibility mechanism for depression. Nat Neurosci 2005; 8: 828-34.
90. Frodl T, Koutsouleris N, Bottlender R, Born C, Jager M, Morgenthaler M, et al. Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Mol Psychiatry 2008; 13: 1093-101.
91. Rao H, Gillihan SJ, Wang J, Korczykowski M, Sankoorikal GM, Kaercher KA, et al. Genetic variation in serotonin transporter alters resting brain function in healthy individuals. Biol Psychiatry 2007; 62: 600-6.
92. Frodl T, Meisenzahl EM, Zetzsche T, Hohne T, Banac S, Schorr C, et al. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry 2004; 65: 492-9.
93. Taylor WD, Steffens DC, Payne ME, MacFall JR, Marchuk DA, Svenson IK, et al. Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry 2005; 62: 537-44.
94. Dannlowski U, Ohrmann P, Bauer J, Deckert J, Hohoff C, Kugel H, et al. 5-HTTLPR biases amygdala activity in response to masked facial expressions in major depression. Neuropsychopharmacology 2008; 33: 418-24.
95. Ruhe HG, Ooteman W, Booij J, Michel MC, Moeton M, Baas F, et al. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics 2009; 19: 67-76.
96. Benedetti F, Bernasconi A, Blasi V, Cadioli M, Colombo C, Falini A, et al. Neural and genetic correlates of antidepressant response to sleep deprivation: A fMRI study of moral valence decision in bipolar depression. Archives of General Psychiatry. [ORIGINAL ARTICLE] 2007; 64: 179-87.
97. Robbins TW. Controlling stress: How the brain protects itself from depression. Nat Neurosci 2005; 8: 261-2.
98. Hamann S. Blue genes: Wiring the brain for depression. Nat Neurosci 2005; 8: 701-3.
99. Ebert D, Berger M. Neurobiological similarities in antidepressant sleep deprivation and psychostimulant use: A psychostimulant theory of antidepressant sleep deprivation. Psychopharmacology (Berl) 1998; 140: 1-10.
100. Benedetti F, Barbini B, Campori E, Colombo C, Smeraldi E. Dopamine agonist amineptine prevents the antidepressant effect of sleep deprivation. Psychiatry Res 1996; 65: 179-84.
101. Benedetti F, Campori E, Barbini B, Fulgosi MC, Colombo C. Dopaminergic augmentation of sleep deprivation effects in bipolar depression. Psychiatry Res 2001; 104: 239-46.
102. Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, Hobi V. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment--neurobiological and psychometric assessment of course. J Psychiatr Res 1994; 28: 381-99.
103. Grunze H, Erfurth A, Walden J. Trimipramine fails to exert antimanic efficacy: A case of the discrepancy between in vitro rationale and clinical efficacy. Clin Neuropharmacol 1999; 22: 298-300.
104. Gessa GL, Pani L, Fadda P, Fratta W. Sleep deprivation in the rat: An animal model of mania. Eur Neuropsychopharmacol 1995; 5 Suppl: 89-93.
105. Tufik S, Lindsey CJ, Carlini EA. Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain? Pharmacology 1978; 16: 98-105.
106. Mogilnicka E. REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats. Pharmacol Biochem Behav 1981; 15: 149-51.
107. Wirz-Justice A, Tobler I, Kafka MS, Naber D, Marangos PJ, Borbely AA, et al. Sleep deprivation: Effects on circadian rhythms of rat brain neurotransmitter receptors. Psychiatry Res 1981; 5: 67-76.
108. Zwicker AP, Calil HM. The effects of REM sleep deprivation on striatal dopamine receptor sites. Pharmacol Biochem Behav 1986; 24: 809-12.
109. Kasper S, Sack DA, Wehr TA, Kick H, Voll G, Vieira A. Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression. Biological Psychiatry 1988; 24: 631-41.
110. Baumgartner A, Riemann D, Berger M. Neuroendocrinological investigations during sleep deprivation in depression. II. Longitudinal measurement of thyrotropin, TH, cortisol, prolactin, GH, and LH during sleep and sleep deprivation. Biolog Psychiatry 1990; 28: 569-87.
111. Ebert D, Kaschka W, Stegbauer P, Schrell U. Prolactin response to sulpiride before and after sleep deprivation in depression. Biolog Psychiatry 1993; 33: 666-9.
112. Ebert D, Albert R, Hammon G, Strasser B, May A, Merz A. Eyeblink rates and depression. Is the antidepressant effect of sleep deprivation mediated by the dopamine system? Neuropsychopharmacology 1996; 15: 332-9.
113. Gerner RH, Post RM, Gillin JC, Bunney WE, Jr. Biological and behavioral effects of one night's sleep deprivation in depressed patients and normals. J Psychiatric Res 1979; 15: 21-40.
114. Benedetti F, Serretti A, Colombo C, Lilli R, Lorenzi C, Smeraldi E. Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression. Psychiatry Res 2003; 118: 241-7.
115. Serretti A, Benedetti F, Colombo C, Lilli R, Lorenzi C, Smeraldi E. Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation. Psychiatry Res 1999; 89: 107-14.
116. Ebert D, Feistel H, Kaschka W, Barocka A, Pirner A. Single photon emission computerized tomography assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation--preliminary results. Biol Psychiatry 1994; 35: 880-5.
117. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res 1999; 90: 91-101.
118. Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 2007; 17(Suppl 1): I171-81.
119. Benedetti F, Colombo C, Pirovano A, Marino E, Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 2008; 203(1): 155-60.
120. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003; 28: 413-20.
121. Sulzer D, Edwards RH. Antidepressants and the monoamine masquerade. Neuron 2005; 46: 1-2.
122. Zhou FM, Liang Y, Salas R, Zhang L, De Biasi M, Dani JA. Corelease of dopamine and serotonin from striatal dopamine terminals. Neuron 2005; 46: 65-74.
123. Arai R, Karasawa N, Geffard M, Nagatsu I. L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: A double-labeling immunofluorescence study. Neurosci Lett 1995; 195: 195-8.
124. Shelton RC, Loosen PT. Sleep deprivation accelerates the response to nortriptyline. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17: 113-23.
125. Siegel JM, Rogawski MA. A function for REM sleep: Regulation of noradrenergic receptor sensitivity. Brain Res 1988; 472: 213-33.
126. Hipolide DC, Moreira KM, Barlow KB, Wilson AA, Nobrega JN, Tufik S. Distinct effects of sleep deprivation on binding to norepinephrine and serotonin transporters in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 297-303.
127. Basheer R, Magner M, McCarley RW, Shiromani PJ. REM sleep deprivation increases the levels of tyrosine hydroxylase and norepinephrine transporter mRNA in the locus coeruleus. Brain Res Mol Brain Res 1998; 57: 235-40.
128. Payne JL, Quiroz JA, Zarate CA, Jr., Manji HK. Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry 2002; 52: 921-6.
129. Amin MM, Khalid R, Khan P. Relationship between sleep deprivation and urinary MHPG levels. Int Pharmacopsychiatry 1980; 15: 81-5.
130. Matussek N, Romisch P, Ackenheil M. MHPG excretion during sleep deprivation in endogenous depression. Neuropsychobiology 1977; 3: 23-9.
131. Muller HU, Riemann D, Berger M, Muller WE. The influence of total sleep deprivation on urinary excretion of catecholamine metabolites in major depression. Acta Psychiatr Scand 1993; 88: 16-20.
132. Cirelli C, Tononi G. Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J Neurosci 2000; 20: 9187-94.
133. Pinna G, Broedel O, Eravci M, Stoltenburg-Didinger G, Plueckhan H, Fuxius S, et al. Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation. Biol Psychiatry 2003; 54: 1049-59.
134. Eker SS, Akkaya C, Sarandol A, Cangur S, Sarandol E, Kirli S. Effects of various antidepressants on serum thyroid hormone levels in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 955-61.
135. Cooper-Kazaz R, Lerer B. Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2008; 11: 685-99.
136. Lass P, Slawek J, Derejko M, Rubello D. Neurological and psychiatric disorders in thyroid dysfunctions. The role of nuclear medicine: SPECT and PET imaging. Minerva Endocrinol 2008; 33: 75-84.
137. Parekh PI, Ketter TA, Altshuler L, Frye MA, Callahan A, Marangell L, et al. Relationships between thyroid hormone and antidepressant responses to total sleep deprivation in mood disorder patients. Biol Psychiatry 1998; 43: 392-4.
138. Szuba MP, Altshuler LL, Baxter LR, Jr. Thyroid function and partial sleep deprivation response. Arch Gen Psychiatry 1992; 49: 581-2.
139. David MM, Owen JA, Abraham G, Delva NJ, Southmayd SE, Wooltorton E, et al. Thyroid function and response to 48-hour sleep deprivation in treatment-resistant depressed patients. Biol Psychiatry 2000; 48: 323-6.
140. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65: 391-426.
141. Martinek S, Inonog S, Manoukian AS, Young MW. A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock. Cell 2001; 105: 769-79.
142. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA 2004; 101: 5099-104.
143. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005; 58: 829-39.
144. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C, et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett 2005; 376: 51-5.
145. Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, et al. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry 2007; 62: 1295-302.
146. Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E. A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004; 368: 123-6.
147. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 2008; 105: 1333-8.
148. Benedetti F, Bernasconi A, Lorenzi C, Pontiggia A, Serretti A, Colombo C, et al. A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett 2004; 355: 37-40.
149. Benedetti F, Dallaspezia S, Colombo C, Pirovano A, Marino E, Smeraldi E. A length polymorphism in the circadian clock gene Per3 influences age at onset of bipolar disorder. Neurosci Lett 2008; 445: 184-7.
150. Benedetti F, Serretti A, Colombo C, Barbini B, Lorenzi C, Campori E, et al. Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet 2003; 123B: 23-6.
151. Benedetti F, Dallaspezia S, Cigala Fulgosi M, Lorenzi C, Serretti A, Barbini B, et al. Actimetric evidence that CLOCK 3111 T/C SNP influences depressive insomnia and activity patterns in bipolar depression. Am J Med Genet B Neuropsychiatr Genet 2007; 144: 631-5.
152. Benedetti F, Radaelli D, Bernasconi A, Dallaspezia S, Falini A, Scotti G, et al. Clock genes beyond the clock: CLOCK genotype biases neural correlates of moral valence decision in depressed patients. Genes Brain Behav 2008; 7: 20-5.
153. Elliott R, Rubinsztein JS, Sahakian BJ, Dolan RJ. The neural basis of mood-congruent processing biases in depression. Arch Gen Psychiatry 2002; 59: 597-604.
154. Deboer T, Vansteensel MJ, Detari L, Meijer JH. Sleep states alter activity of suprachiasmatic nucleus neurons. Nat Neurosci 2003; 6: 1086-90.
155. Cirelli C, Tononi G. Gene expression in the brain across the sleep-waking cycle. Brain Res 2000; 885: 303-21.
156. Tononi G, Cirelli C. Sleep function and synaptic homeostasis. Sleep Med Rev 2006; 10: 49-62.
157. Massimini M, Ferrarelli F, Huber R, Esser SK, Singh H, Tononi G. Breakdown of cortical effective connectivity during sleep. Science 2005; 309: 2228-32.
158. Tononi G, Cirelli C. Sleep and synaptic homeostasis: A hypothesis. Brain Res Bull 2003; 62: 143-50.
159. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455: 894-902.
160. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002; 7(Suppl 1): S71-80.
161. Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 2007; 6: 87-100.
162. Palucha A, Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007; 115: 116-47
163. Bleakman D, Alt A, Witkin JM. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets 2007; 6: 117-26.
164. Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic
165. Maeng S, Zarate CA, Jr. The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007; 9: 467-74.
166. Benedetti F, Calabrese G, Bernasconi A, Cadioli M, Colombo C, Dallaspezia S, et al. Spectroscopic correlate of antidepressant response to sleep deprivation and light therapy: A 3.0 T study of bipolar depression. Psychiatry Research in press.
167. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156: 675-82.
168. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: Towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65: 193-207.
169. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC, et al. Anterior cingulate activity as a predictor of degree of treatment response in major depression: Evidence from brain electrical tomography analysis. Am J Psychiatry 2001; 158: 405-15.
170. Hunter AM, Leuchter AF, Morgan ML, Cook IA. Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry 2006; 163: 1426-32.
171. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-37.
172. Smith GS, Reynolds CF, 3rd, Pollock B, Derbyshire S, Nofzinger E, Dew MA, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatry 1999; 156: 683-9.
173. Clark CP, Brown GG, Frank L, Thomas L, Sutherland AN, Gillin JC. Improved anatomic delineation of the antidepressant response to partial sleep deprivation in medial frontal cortex using perfusion-weighted functional MRI. Psychiatry Res 2006; 146: 213-22.
174. Clark CP, Brown GG, Archibald SL, Fennema-Notestine C, Braun DR, Thomas LS, et al. Does amygdalar perfusion correlate with antidepressant response to partial sleep deprivation in major depression? Psychiatry Res 2006; 146: 43-51.
175. Ridderinkhof KR, Ullsperger M, Crone EA, Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science 2004; 306: 443-7
176. Davidson RJ, Irwin W, Anderle MJ, Kalin NH. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003; 160: 64-75.
177. Levesque J, Eugene F, Joanette Y, Paquette V, Mensour B, Beaudoin G, et al. Neural circuitry underlying voluntary suppression of sadness. Biol Psychiatry 2003; 53: 502-10.
178. Blair KS, Smith BW, Mitchell DG, Morton J, Vythilingam M, Pessoa L, et al. Modulation of emotion by cognition and cognition by emotion. Neuroimage 2007; 35: 430-40.
179. Wu JC, Gillin JC, Buchsbaum MS, Schachat C, Darnall LA, Keator DB, et al. Sleep deprivation PET correlations of Hamilton symptom improvement ratings with changes in relative glucose metabolism in patients with depression. J Affect Disord 2008; 107: 181-6.
180. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med 2008 Nov 18; 149(10): 734-50.
181. Janackova S, Sforza E. Neurobiology of sleep fragmentation: Cortical and autonomic markers of sleep disorders. Curr Pharm Des 2008; 14(32): 3474-80.
182. Muller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des 2008; 14(14): 1452-65.